Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 3:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 94 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Lorazepam (drug) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effects of GW876008 on Brain Activation During Emotional Processing in Healthy Subjects.

NCT00424697
View directory record Official record
Conditions
Healthy Subjects
Interventions
placebo, lorazepam, GW876008
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2010 · Synced Oct 11, 2026, 3:42 AM EDT
Completed Phase 2 Interventional

Therapies for Down Syndrome Regression Disorder

NCT05662228
View directory record Official record
Conditions
Down Syndrome, Regression
Interventions
Lorazepam, Intravenous immunoglobulin (IVIG), Tofacitinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 30 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 11, 2026, 3:42 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

NCT01949662
View directory record Official record
Conditions
Advanced Cancers
Interventions
Lorazepam, Placebo, Haloperidol decanoate, Questionnaires
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 11, 2026, 3:42 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Acute Effect of Lorazepam on Brain Activity Measured by Magnetoencephalograpy (MEG) and Electroencephalography (EEG)

NCT01272778
View directory record Official record
Conditions
Healthy Subjects
Interventions
Lorazepam, Placebo
Drug
Lead sponsor
Orasi Medical, Inc.
Industry
Eligibility
18 Years to 35 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Elk Grove Village, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Oct 11, 2026, 3:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Lorazepam, Diphenhydramine Hydrochloride, and Haloperidol Gel in Healthy Volunteers

NCT01204255
View directory record Official record
Conditions
Healthy
Interventions
lorazepam, diphenhydramine hydrochloride, haloperidol, questionnaire administration, laboratory biomarker analysis
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 11, 2026, 3:42 AM EDT
Terminated Phase 1 Interventional

How Your Patients' Non-REM Sleep Changes On Sedatives in the Intensive Care Units

NCT00826553
View directory record Official record
Conditions
Delirium, Respiratory Failure
Interventions
Dexmedetomidine, GABA agonist
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 11, 2026, 3:42 AM EDT
Completed No phase listed Observational

Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)

NCT01810458
View directory record Official record
Conditions
Liver Fibrosis, Alpha-1 Antitrypsin Deficiency, AAT Deficiency, AATD
Interventions
Abdominal ultrasound, History and physical, Intravenous catheter, Blood draw, Liver questionnaire, Liver Biopsy, Midazolam, Fentanyl, Lidocaine, Acetaminophen, Lorazepam, Oxycodone/Acetaminophen, Ondansetron
Device · Procedure · Other + 1 more
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 11, 2026, 3:42 AM EDT
Withdrawn Phase 4 Interventional

Ziprasidone vs Standard Therapy for Agitated Patients in the ED

NCT00786318
View directory record Official record
Conditions
Psychosis, Agitation, Delirium
Interventions
ziprasidone, Standard therapy
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 11, 2026, 3:42 AM EDT
Terminated Early Phase 1 Interventional

Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)

NCT00881556
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
Palifermin, Fludarabine, Busulfan, Lorazepam, Alemtuzumab, Tacrolimus
Drug
Lead sponsor
Columbia University
Other
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Aurora, Colorado • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 11, 2026, 3:42 AM EDT
Completed No phase listed Observational

Treatment of Alcohol Withdrawal Syndrome With Alpha-2 Agonists and/or Anticonvulsants

NCT05438641
View directory record Official record
Conditions
Alcohol Withdrawal Syndrome
Interventions
BZDP-Sparing Protocol, BZDP-Based Protocol
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 11, 2026, 3:42 AM EDT
Completed Not applicable Interventional

Ketamine for Pain Control After Severe Traumatic Injury

NCT04274361
View directory record Official record
Conditions
Hospital Inpatient Trauma Injury, Pain Management
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 64 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 11, 2026, 3:42 AM EDT
Not listed Phase 4 Interventional

Phenobarbital vs Ativan for Alcohol Withdrawal in the Intensive Care Unit

NCT04156464
View directory record Official record
Conditions
Alcohol Withdrawal, Alcohol Withdrawal Delirium
Interventions
Phenobarbital, Lorazepam
Drug
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 11, 2026, 3:42 AM EDT
Terminated Not applicable Interventional Results available

The Use of Clonidine in Pain and Anxiety Associated With Acute Burn Injury in Children

NCT00580151
View directory record Official record
Conditions
Pain, Anxiety
Interventions
clonidine, placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
4 Years to 20 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 11, 2026, 3:42 AM EDT
Recruiting Phase 2 Interventional

5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

NCT05317000
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Combination 5-azacytidine and nivolumab, Nivolumab
Drug
Lead sponsor
Barbara Burtness
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 11, 2026, 3:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Hallucinogens and Other Drugs on Mood and Performance

NCT02033707
View directory record Official record
Conditions
Healthy
Interventions
Hallucinogens and psychoactive substances
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Oct 11, 2026, 3:42 AM EDT
Completed Phase 3 Interventional Results available

EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)

NCT02305797
View directory record Official record
Conditions
Generalized Anxiety Disorder (GAD)
Interventions
Extended-release lorazepam, Placebo
Drug
Lead sponsor
Edgemont Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Multiple Locations, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 11, 2026, 3:42 AM EDT
Not listed Phase 4 Interventional

Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder

NCT06093451
View directory record Official record
Conditions
Schizophrenia Agitation, Schizo Affective Disorder, Bipolar Disorder, Dexmedetomidine
Interventions
Dexmedetomidine, Lorazepam 2 MG/ML
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 11, 2026, 3:42 AM EDT
Completed Phase 1 Interventional

Psilocybin for Treatment of Obsessive Compulsive Disorder

NCT03300947
View directory record Official record
Conditions
Obsessive-compulsive Disorder (OCD)
Interventions
Psilocybin 100 mcg/kg, Psilocybin 300 mcg/kg, Lorazepam 1 mg
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 30, 2024 · Synced Oct 11, 2026, 3:42 AM EDT
Completed Not applicable Interventional

Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder

NCT00715039
View directory record Official record
Conditions
Anxiety Disorders
Interventions
lorazepam, placebo, paroxetine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
15
States / cities
Glendale, California • Northridge, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2008 · Synced Oct 11, 2026, 3:42 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Pentostatin and Targeted Busulfan

NCT00496340
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Pentostatin, Busulfan, Rituximab, Allogeneic Hematopoietic Cell Transplant
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 5, 2014 · Synced Oct 11, 2026, 3:42 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Prescribing Lorazepam for IUD Insertion: Pilot Feasibility Study

NCT06496854
View directory record Official record
Conditions
Pain, IUD
Interventions
Lorazepam 1 mg, Ibuprofen 800 mg
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 11, 2026, 3:42 AM EDT
Recruiting Phase 2 Interventional

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424
View directory record Official record
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 11, 2026, 3:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Biological Basis of Individual Variation in Social Cooperation

NCT01566539
View directory record Official record
Conditions
Healthy
Interventions
Intranasal Oxytocin (OT) 24 IU, Intranasal Vasopressin (AVP), Intranasal Placebo, Intranasal Vasopressin (AVP) 40 IU, Lorazepam
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 30 Years
Enrollment
707 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 11, 2026, 3:42 AM EDT
Recruiting Phase 2 Interventional

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

NCT06591091
View directory record Official record
Conditions
Depression
Interventions
Clemastine Fumarate, Placebo
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 11, 2026, 3:42 AM EDT